Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (610) Arrow Down
Filter Results: (610) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (610)
    • People  (4)
    • News  (110)
    • Research  (426)
    • Events  (3)
    • Multimedia  (4)
  • Faculty Publications  (259)

Show Results For

  • All HBS Web  (610)
    • People  (4)
    • News  (110)
    • Research  (426)
    • Events  (3)
    • Multimedia  (4)
  • Faculty Publications  (259)
← Page 11 of 610 Results →
  • 06 Jun 2023
  • Cold Call Podcast

The Opioid Crisis, CEO Pay, and Shareholder Activism

Keywords: Re: Suraj Srinivasan; Pharmaceutical; Pharmaceutical; Pharmaceutical
  • January 2014 (Revised December 2014)
  • Case

GenapSys: Business Models for the Genome

By: Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble

GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and... View Details

Keywords: DNA Sequencing; Life Sciences; Business Model; Innovation & Entrepreneurship; Health Care and Treatment; Genetics; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Hamermesh, Richard G., Joseph B. Fuller, and Matthew Preble. "GenapSys: Business Models for the Genome." Harvard Business School Case 814-050, January 2014. (Revised December 2014.)
  • Research Summary

The Transparency of Ethical Behavior

(with Max Bazerman, Karim Kassam, and Neeru Paharia)
This research analyzes how unethical behavior is viewed when performed... View Details
  • May 2023 (Revised June 2023)
  • Case

Novartis (A): Reimagining Medicine

By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Leadership; Pharmaceutical Industry; Switzerland
Citation
Educators
Related
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (A): Reimagining Medicine." Harvard Business School Case 723-443, May 2023. (Revised June 2023.)
  • November 2017
  • Case

The 'Wonder Drug' That Killed Babies

By: Joshua Lev Krieger, Tom Nicholas and Matthew Preble
In the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a certain stage of fetal development. As many as 10,000 children... View Details
Keywords: Regulation; Business and Government Relations; Business and Community Relations; Business and Stakeholder Relations; Product Marketing; Corporate Social Responsibility and Impact; Business History; Health; Government Legislation; Corporate Accountability; Ethics; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; Pharmaceutical Industry; United States; United Kingdom; Australia; Germany; Europe
Citation
Educators
Purchase
Related
Krieger, Joshua Lev, Tom Nicholas, and Matthew Preble. "The 'Wonder Drug' That Killed Babies." Harvard Business School Case 818-044, November 2017.
  • 2011
  • Working Paper

Managing Political Risk in Global Business: Beiersdorf 1914-1990

By: Geoffrey Jones and Christina Lubinski
This working paper examines corporate strategies of political risk management during the twentieth century. It focuses especially on Beiersdorf, a German-based pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks... View Details
Keywords: History; Risk Management; Business History; Multinational Firms and Management; Corporate Strategy; Intellectual Property; Cooperation; Business and Government Relations; Germany
Citation
Read Now
Related
Jones, Geoffrey, and Christina Lubinski. "Managing Political Risk in Global Business: Beiersdorf 1914-1990." Harvard Business School Working Paper, No. 12-003, July 2011.
  • May 2023 (Revised June 2023)
  • Supplement

Novartis (B): Reimagining Medicine

By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
Keywords: Health Care and Treatment; Business Model; Production; Business Strategy; Pharmaceutical Industry
Citation
Related
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
  • 02 Aug 2011
  • First Look

First Look: August 2

pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks revealed its vulnerability to political risk. Following the advent of the Nazi regime in 1933, the largely Jewish owned and managed... View Details
Keywords: Sean Silverthorne
  • 03 Apr 2007
  • First Look

First Look: April 3, 2007

the inception of the company in 1999. eClinicalWorks was a privately run business in the healthcare information technology field that took in $25 million in revenue in 2005. Revenues for 2006 were projected to reach $40 million. This... View Details
Keywords: Martha Lagace
  • 07 Jan 2010
  • Working Paper Summaries

International Differences in the Size and Roles of Corporate Headquarters: An Empirical Examination

Keywords: by David Collis, David Young & Michael Goold

    Dafna Bearson

    Dafna Bearson is a doctoral candidate in the Strategy Unit at Harvard Business School. Her research interests lie at the intersection of strategy and innovation. Specifically, her research focuses on intellectual property commercialization strategy in startups... View Details

    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals
    • Web

    Faculty & Advisors | MBA

    Alexion Pharmaceuticals from 2017-2019. At Biogen, Paul oversaw rapid growth in the company as it expanded it's products and pipeline. During his tenure as CFO, Biogen grew total return to shareholders at a... View Details
    • May 2021
    • Case

    The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease

    By: Amitabh Chandra, Spencer Lee-Rey and Caroline Marra
    This case explores incentives for rare disease drug development by chronicling the role of the Spinal Muscular Atrophy (SMA) Foundation in forming strategic partnerships with the scientific research community and pharmaceutical developers to transform the trajectory... View Details
    Keywords: Innovation and Invention; Strategy; Business or Company Management; Society; Health; Public Administration Industry; Health Industry; United States
    Citation
    Educators
    Purchase
    Related
    Chandra, Amitabh, Spencer Lee-Rey, and Caroline Marra. "The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease." Harvard Business School Case 621-112, May 2021.

      Krishna G. Palepu

      KRISHNA G. PALEPU is the Ross Graham Walker Professor of Business Administration, and has served previously as Senior Advisor to the President of Harvard University, and Senior Associate Dean at the... View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

        Max H. Bazerman

        Max H. Bazerman is Jesse Isidor Straus Professor of Business Administration at the Harvard Business School. His recent books... View Details
        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals
        • October 2022
        • Case

        Cost Plus Drugs

        By: Alexander MacKay and James Barnett
        In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies.... View Details
        Keywords: Business Ventures; Decision Making; Entrepreneurship; Ethics; Health; Markets; Social Enterprise; Society; Strategy; Health Care and Treatment; Business Divisions; Factories, Labs, and Plants; Pharmaceutical Industry; Pharmaceutical Industry; United States; Texas
        Citation
        Educators
        Purchase
        Related
        MacKay, Alexander, and James Barnett. "Cost Plus Drugs." Harvard Business School Case 723-362, October 2022.
        • November 2016 (Revised February 2017)
        • Case

        CVS Health: Redefining the Value Proposition

        By: Michael E. Porter, Jorge Ramirez-Vallejo and Alexandra Houghtalin
        This case explores how a company can use shared value as a lens to think about competition and strategy choices in a challenging and evolving industry. The case takes a historical look at the structure of the retail pharmacy industry and the changing nature of rivalry... View Details
        Keywords: Shared Value; Pharmacy; Health Care; Strategy; Competitive Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States
        Citation
        Educators
        Purchase
        Related
        Porter, Michael E., Jorge Ramirez-Vallejo, and Alexandra Houghtalin. "CVS Health: Redefining the Value Proposition." Harvard Business School Case 717-436, November 2016. (Revised February 2017.)
        • June 2024 (Revised December 2024)
        • Case

        Lana Ghanem: Pushing the Boundaries of Health Care Through Venture Capital

        By: Joshua D. Margolis and Ahmed Dahawy
        Lana Ghanem, managing director of Hikma Ventures, the corporate venture arm of larger pharmaceutical group Hikma, is considering how to grow the venture arm as well as progress her own career. Over the past few years Hikma's executive team had been pressuring the... View Details
        Keywords: Business Divisions; Corporate Entrepreneurship; Investment; Corporate Governance; Health Care and Treatment; Leadership Development; Business or Company Management; Growth and Development Strategy; Business Strategy; Venture Capital; Personal Development and Career; Pharmaceutical Industry; Pharmaceutical Industry; Jordan
        Citation
        Educators
        Purchase
        Related
        Margolis, Joshua D., and Ahmed Dahawy. "Lana Ghanem: Pushing the Boundaries of Health Care Through Venture Capital." Harvard Business School Case 424-075, June 2024. (Revised December 2024.)
        • January 2009
        • Case

        When Supply is of Public Interest: Roche & Tamiflu

        The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic... View Details
        Keywords: Global Strategy; Health Pandemics; Distribution; Logistics; Production; Supply Chain Management; Performance Capacity; Pharmaceutical Industry
        Citation
        Educators
        Purchase
        Related
        Watson, Noel H., Laura Rock Kopczak, and Prashant Yadav. "When Supply is of Public Interest: Roche & Tamiflu." Harvard Business School Case 609-061, January 2009.
        • December 2018
        • Case

        Corporate Transformation at Merck KGaA, Darmstadt, Germany

        By: Joseph B. Fuller, Amy C. Edmondson, Daniela Beyersdorfer and Tonia Labruyere
        When Stefan Oschmann became CEO and chairman of the executive board of Merck KGaA, Darmstadt, Germany, in 2016, the company had started its transformation from a mid-tier traditional German industry player to a global modern science and technology player. The... View Details
        Keywords: Corporate Governance With Family Ownership; Transformation; Change Management; Restructuring; Corporate Governance; Family Ownership
        Citation
        Educators
        Purchase
        Related
        Fuller, Joseph B., Amy C. Edmondson, Daniela Beyersdorfer, and Tonia Labruyere. "Corporate Transformation at Merck KGaA, Darmstadt, Germany." Harvard Business School Case 319-072, December 2018.
        • ←
        • 11
        • 12
        • …
        • 30
        • 31
        • →
        ǁ
        Campus Map
        Harvard Business School
        Soldiers Field
        Boston, MA 02163
        →Map & Directions
        →More Contact Information
        • Make a Gift
        • Site Map
        • Jobs
        • Harvard University
        • Trademarks
        • Policies
        • Accessibility
        • Digital Accessibility
        Copyright © President & Fellows of Harvard College.